Gene Signature That Predicts Prostate Cancer Survival Discovered

Researchers have identified a six-gene signature that help predict prostate cancer survival. The study published in The Lancet Oncology demonstrates the usefulness of prognostic markers.

Researchers have identified a six-gene signature that help predict prostate cancer survival. The study published in The Lancet Oncology demonstrates how prognostic markers may be useful in a clinical setting.

Using blood from 202 men with treatment-resistant prostate cancer, researchers found six genes characteristic of treatment-resistant prostate cancer. Men with the six-gene signature were high-risk, with a survival time of 7.8 months, and men without it were low-risk, with a survival time of approximately 34.9 months. A replication study of 140 additional patients validated these findings. William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology of The Tisch Cancer Institute at The Mount Sinai Medical Center, led the research team.

Prostate Cancer: Treatment Options - Surgery, Radiation Therapy, Hormone Therapy
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemotherapy, cryosurgery or biologic therapy.

"There is an urgent need for predictive models that help assess how aggressive the disease is in prostate cancer patients, as survival can vary greatly," said Dr. Oh. "Our six-gene model, delivered in a simple blood test, will allow clinicians to better determine the course of action for their patients, determine clinical trial eligibility, and lead to more targeted studies in late-stage disease."

Until now, disease prognosis in advanced prostate cancer could only be determined through clinical predictors or, occasionally, tumor biopsies with only moderately predictive results. This study shows the efficacy of the six-gene model blood test in determining length of survival.

"The genes noted in the model suggest possible changes in the immune system related to late-stage disease that warrant further study as a target for immune-based therapies," said Dr. Oh.

Prostate Specific Antigen [PSA] & Prostate Cancer Diagnosis
PSA blood test is specific to prostate gland but not necessarily a cancer specific test but is commonly used to diagnose prostate cancer.

Dr. Oh's team is conducting additional studies exploring the feasibility of the six-gene signature in other types of prostate cancer, the stability of the signature during the course of a patient's illness, and the predictive ability of this signature in patients with prostate cancer treated with immune-based therapies.

Source-Eurekalert

Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!

Foods That Boost Men's Health
Heart Disease and Cancer are the major killers for men above the age of 40. Cholesterol lowering through diet, lifestyle, and medications should be considered as the "real male multivitamin".